ANNOVIS BIO INC. COMMON STOCK

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

27 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

25 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

21 Mar 2025 17:05:30 By Nasdaq GlobeNewswire

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Annovis to Host Patients’ Live Forum on February 27, 2025

19 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

07 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

04 Feb 2025 16:31:00 By Nasdaq GlobeNewswire

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

03 Feb 2025 06:22:46 By Nasdaq GlobeNewswire

Annovis Bio, Inc. Announces Proposed Public Offering

31 Jan 2025 20:14:02 By Nasdaq GlobeNewswire

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

14 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

07 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Annovis to Host Year-End Investor Webcast on December 11, 2024

25 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

12 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

11 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

22 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

03 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

02 Oct 2024 08:30:00 By Nasdaq GlobeNewswire